Human epidermal growth factor receptor 2-targeted therapies in breast cancer

• Type of Material: Article
• Authors: Rita Nahta, Emory University
• Language: English
• Date: 2013-07-01
• Publisher: Taylor & Francis: STM, Behavioural Science and Public Health Titles - No Open Select
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2013 Informa UK, Ltd.
• Final Published Version (URL): http://dx.doi.org/10.1517/14712598.2013.789497
• Title of Journal or Parent Work: Expert Opinion on Biological Therapy
• ISSN: 1471-2598
• Volume: 13
• Issue: 7
• Start Page: 949
• End Page: 952
• Keywords: Life Sciences & Biomedicine; lapatinib; erbB2; HER2; Medicine, Research & Experimental; EXTRACELLULAR REGION; PERTUZUMAB; trastuzumab; SURVIVAL; CELLS; COMPLEX; HER3; breast cancer; Science & Technology; AMPLIFICATION; Biotechnology & Applied Microbiology; pertuzumab; Research & Experimental Medicine; TRASTUZUMAB
• Research Categories: Health Sciences, Oncology; Health Sciences, Pharmacology

Abstract

Human epidermal growth factor receptor 2 (HER2) was acknowledged as an important therapeutic target in breast cancer more than 25 years ago. Subsequently, significant basic science and translational discoveries have resulted in the approval of four HER2-targeted therapies over the past 15 years. This editorial discusses future challenges regarding selection and development of treatments for HER2-positive breast cancer, which can only be met by continuing to support research efforts into the basic mechanisms by which cancer cells escape targeted therapies. Identifying specific molecular mechanisms underlying the sensitivity or resistance to each HER2-targeted agent will ultimately allow individualized therapy for each patient.